Paragon Biosciences
@ParagonBiosci
Followers
95
Following
44
Media
31
Statuses
67
Paragon is a global life science leader that creates, build and funds innovative biology-based companies to accelerate scientific breakthroughs.
Joined November 2017
Excited to have life science supporters @BainCapVC & Valor Equity Partners participating in an upsized and oversubscribed $250 million funding round for our portfolio company Emalex Biosciences.
emalexbiosciences.com
Clinical stage biopharmaceutical company completes upsized, oversubscribed Series D financing from leading life sciences investors CHICAGO—November 3, 2022—Emalex Biosciences announced the closing of...
1
0
0
Our latest newsletter is out! Read about the recent achievements of Paragon and its portfolio companies here: @CastleCreekBio @evozyne @HarmonyBio.
0
0
2
The most fun image & video creation tool in the world is here. Try it for free in the Grok App.
0
160
2K
Our portfolio company, @evozyne, announced its second strategic collaboration with @TakedaPharma to develop next-generation gene therapies for up to four rare disease targets. This agreement could result in up to $400 million of payments. Read more:
evozyne.com
Evozyne leverages Generative AI to scalably, rapidly and repeatedly design precision life-changing novel protein therapeutics for patients. We engineer new proteins that function in ways that were...
0
0
0
Our unique portfolio companies focus on solving some of society’s most challenging problems. Learn more about us and the exceptional work of our companies:
0
0
0
Emalex Biosciences, a Paragon portfolio company, completed a licensing agreement for a potential treatment for Restless Legs Syndrome w/augmentation. Read more:
0
0
0
RT @MATTERhealth: On March 10, @UChicago Chancellor, Trustee and President Emeritus Robert Zimmer will sit down with @ParagonBiosci Founder….
0
2
0
#ICYMI: Excellent news: Emalex Biosciences, a Paragon portfolio company, received positive topline results from its Phase 2b clinical study evaluating a first-in-class investigational therapy for pediatric patients with #TouretteSyndrome. Read more here:
emalexbiosciences.com
Statistically significant, clinically meaningful results obtained on the primary and multiple secondary efficacy endpoints; ecopipam well tolerated in the study
0
0
1
RT @CastleCreekBio: Attending the BIO CEO & Investor Conference next week? Registrants can join Castle Creek Biosciences President & CEO Ma….
0
1
0
Heart disease is the leading cause of death in the U.S. There are many practical ways to reduce your risk through self-care, such as managing stress, improving sleep habits, keeping up with medical appointments and increasing physical activity. @TheHeartTruth #ourhearts
0
0
0
Check out the work being done at our portfolio company, @evozyne. It’s harnessing the power of novel proteins to improve health and the environment. Senior Scientist Guy Bushkin explains more here: via @YouTube #proteins #innovation
0
1
2
RT @CastleCreekBio: We have acquired Novavita Thera, a preclinical #genetherapy company focused on rare liver and metabolic diseases, furth….
0
2
0
As 2021 comes to an end, we’ve put together a recap of some of the outstanding accomplishments by Paragon and our portfolio companies this year. Check it out:
0
0
1
It’s official! We have been certified as a Great Place to Work. Proud of the work we do and the team that supports it. Read more:
0
1
2
RT @CastleCreekBio: #ICYMI we’ve announced a research collaboration with the @MayoClinic to advance discovery and pre-clinical development….
bizjournals.com
The research partnership will focus on two rare genetic connective tissue disorders.
0
1
0
Proud of our portfolio company @evozyne on winning a Chicago Inno’s Fire Award. One of 50 companies honored for its notable work and impact on the city’s tech scene this past year. Learn more about Evozyne and the potential of its optimized proteins:
0
1
3
RT @HarmonyBio: At Harmony, we keep #raredisease patients at the heart of everything we do and are pleased to share an exciting update for….
0
2
0
RT @CastleCreekBio: Our Chief Medical Officer, Mary Spellman, MD, FAAD is presenting a lecture on our autologous gene therapy program for d….
0
3
0
Excellent news: Emalex Biosciences, a Paragon portfolio company, received positive topline results from its Phase 2b clinical study evaluating a first-in-class therapy for pediatric patients with #TouretteSyndrome. Read more here: #tourettes.
0
0
0